STAT Plus: Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy
Vertex has sparked anger among cystic fibrosis patients by requesting extra time to submit evidence for a new therapy to a U.K. cost-effectiveness agency
No hay comentarios:
Publicar un comentario